Effector stage CC chemokine receptor-1 selective antagonism reduces multiple sclerosis-like rat disease.

Authors: Eltayeb, S  Sunnemark, D  Berg, AL  Nordvall, G  Malmberg, A  Lassmann, H  Wallstrom, E  Olsson, T  Ericsson-Dahlstrand, A 
Citation: Eltayeb S, etal., J Neuroimmunol. 2003 Sep;142(1-2):75-85.
Pubmed: (View Article at PubMed) PMID:14512166

We have studied the role of the chemokine receptor CCR1 during the effector stage of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in DA rats. In situ hybridization histochemistry revealed local production of the CCR1 ligands CCL3 (MIP-1 alpha) and CCL5 (RANTES), as well as large numbers of CCR1 and CCR5 expressing cells within inflammatory brain lesions. A low-molecular weight CCR1 selective antagonist potently abrogated both clinical and histopathological disease signs during a 5-day treatment period, without signs of peripheral immune compromise. Thus, we demonstrate therapeutic targeting of CCR1-dependent leukocyte recruitment to the central nervous system in a multiple sclerosis (MS)-like rat model.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 5688167
Created: 2012-02-20
Species: All species
Last Modified: 2012-02-20
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.